EP1225907A4 - INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODIC VIRUS-1 (HIV-1) BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS - Google Patents

INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODIC VIRUS-1 (HIV-1) BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS

Info

Publication number
EP1225907A4
EP1225907A4 EP00972031A EP00972031A EP1225907A4 EP 1225907 A4 EP1225907 A4 EP 1225907A4 EP 00972031 A EP00972031 A EP 00972031A EP 00972031 A EP00972031 A EP 00972031A EP 1225907 A4 EP1225907 A4 EP 1225907A4
Authority
EP
European Patent Office
Prior art keywords
immunodic
hiv
virus
peptide
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00972031A
Other languages
German (de)
French (fr)
Other versions
EP1225907A1 (en
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Brian D Livingston
Robert Chesnut
Denise Marie Baker
Esteban Celis
Ralph T Kubo
Howard M Grey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1225907A1 publication Critical patent/EP1225907A1/en
Publication of EP1225907A4 publication Critical patent/EP1225907A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP00972031A 1999-10-05 2000-10-05 INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODIC VIRUS-1 (HIV-1) BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS Withdrawn EP1225907A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41286399A 1999-10-05 1999-10-05
US412863 1999-10-05
PCT/US2000/027766 WO2001024810A1 (en) 1999-10-05 2000-10-05 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Publications (2)

Publication Number Publication Date
EP1225907A1 EP1225907A1 (en) 2002-07-31
EP1225907A4 true EP1225907A4 (en) 2005-06-22

Family

ID=23634801

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00972031A Withdrawn EP1225907A4 (en) 1999-10-05 2000-10-05 INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODIC VIRUS-1 (HIV-1) BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS

Country Status (5)

Country Link
EP (1) EP1225907A4 (en)
JP (1) JP4873810B2 (en)
AU (1) AU1075001A (en)
CA (1) CA2386499A1 (en)
WO (1) WO2001024810A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US7790171B1 (en) 2000-08-25 2010-09-07 Centre National De La Recherche Scientifique (C.N.R.S.) Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase
FR2824326B1 (en) * 2001-05-04 2004-03-19 Commissariat Energie Atomique MIXTURE OF PEPTIDES FROM PAPILLOMAVIRUS E6 AND / OR E7 PROTEINS AND THEIR APPLICATIONS
ES2274100T3 (en) * 2001-09-07 2007-05-16 Polymun Scientific Immunbiologische Forschung Gmbh ANTIBODIES RECOGNIZING A PEPTIDE THAT IMITATES A CRIPTIC EPITHOPE OF GP41 OF HIV-1.
CA2357906A1 (en) * 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
KR20040040475A (en) * 2001-09-28 2004-05-12 가부시키가이샤 디나벡크 겐큐쇼 Mammalian cell-infecting virus vector encoding epitope-bound β2m and utilization thereof
ES2605445T3 (en) * 2001-11-26 2017-03-14 Hivih Protein-protein interactions in the human immunodeficiency virus
AU2003207835A1 (en) * 2002-02-04 2003-09-02 Auburn University Peptides for recognition and targeting of glial cell tumors
EP1431306A1 (en) * 2002-12-19 2004-06-23 Creabilis Therapeutics s.r.l. A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism
CA2497890A1 (en) * 2002-09-13 2004-03-25 Creabilis Therapeutics S.P.A. A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism
ATE520708T1 (en) 2003-03-28 2011-09-15 Us Gov Health & Human Serv IMMUNOGENETIC HIV-1 MULTI-CLADE, MULTIVALENT CONSTRUCTS AND THEIR USE
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
WO2004106365A2 (en) * 2003-05-28 2004-12-09 Aventis Pasteur, Inc. Modulatory peptide motifs for inducing th1 or th2 immune response
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US20050112139A1 (en) * 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
EP1697399B1 (en) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
WO2005116055A1 (en) * 2004-05-24 2005-12-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptides, antibodies and compositions containing same useful for treating hiv virus infection
FR2874612A1 (en) * 2004-08-27 2006-03-03 Commissariat Energie Atomique HLA-DP4-RESTRICTED HIV CD4 + EP TOTES AND USES THEREOF
US8029797B2 (en) 2005-03-01 2011-10-04 Variation Biotechnologies Inc. Multivalent HIV immunogenic compositions comprising a pool of lipidated and nonlipidated peptides representing Gag and Env variable regions
US7501398B2 (en) * 2005-07-22 2009-03-10 Universita'degli Studi Di Milano Inhibitor of the folding of the HIV-1-protease as antiviral agent
BRPI0504117A (en) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epitopes, combination of epitopes, uses of epitopes or their combination, composition, uses of composition, anti-HIV-1 prophylactic vaccines, therapeutic vaccines, method for identifying epitopes and methods for treatment or prevention.
ES2616341T3 (en) * 2006-03-10 2017-06-12 Peptcell Limited HIV regulatory or accessory protein peptides, compositions and their use
DE602007010127D1 (en) * 2006-06-01 2010-12-09 Statens Seruminstitut Hiv-impfstoff
WO2008068765A2 (en) * 2006-12-07 2008-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions and methods for inhibiting hiv-1 replication and integrase activity
EA017887B1 (en) 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Multimeric multiepitope influenza vaccines
JP2010536885A (en) * 2007-08-24 2010-12-02 ノバルティス アーゲー HIVENV protein with modifications in the V3 loop
WO2009043155A2 (en) * 2007-10-03 2009-04-09 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Distinct hiv-1 gag and env epitopes of hla alleles associated with differential susceptibility to hiv-1 infection
WO2010011343A2 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Methods for treating viral disorders
WO2010041241A2 (en) 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Hiv-1 integrase derived peptides and compositions
EP2391635B1 (en) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
WO2011008863A2 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
ES2358829B1 (en) 2009-10-23 2012-06-25 Lipotec, S.A. USEFUL PEPTIDES IN THE TREATMENT AND / OR CARE OF SKIN, MUCOSES AND / OR HAIR AND ITS USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS.
CA2817418A1 (en) * 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2452947A1 (en) 2010-11-16 2012-05-16 Münch, Jan Viral infection enhancing peptide
WO2012114323A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
CA2833425C (en) * 2011-04-07 2018-08-21 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Protease cleavage site peptides as an hiv vaccine
US9327009B2 (en) * 2012-03-02 2016-05-03 Council Of Scientific And Industrial Research Peptide inhibitors as novel anti-HIV therapeutics
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
KR101476255B1 (en) * 2014-02-07 2014-12-26 대한민국 Recombinant peptide having T cell epitope derived from HIV-1 and vaccine composition comprising thereof
ES2959642T3 (en) * 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services METHODS AND COMPOSITIONS TO INDUCE AN IMMUNE RESPONSE THROUGH CONSTRUCTIONS WITH CONSERVED ELEMENTS
CA3045756A1 (en) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Hiv binding agents
GB2549798A (en) * 2016-04-29 2017-11-01 Univ Bradford Peptides and nanoparticle formulations thereof
WO2018067582A2 (en) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv-1 env fusion peptide immunogens and their use
WO2020092705A1 (en) * 2018-10-31 2020-05-07 University Of Virginia Patent Foundation Self-assembling peptides and hydrogels
IT202000019708A1 (en) * 2020-08-07 2022-02-07 Ospedale Pediatrico Bambino Gesù Angiotensin-converting enzyme 2 (ACE2) receptor-binding peptides and their medical uses
CA3192758A1 (en) * 2020-09-04 2022-03-10 Dompe' Farmaceutici Spa Peptides endowed with angiogenic activity

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A2 (en) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of HIV-1 infection
WO1992022577A1 (en) * 1991-06-17 1992-12-23 Neovacs Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US5736142A (en) * 1993-09-14 1998-04-07 Cytel Corporation Alteration of immune response using pan DR-binding peptides
WO1999049893A1 (en) * 1998-03-31 1999-10-07 Trustees Of Boston University Methods for designing molecular conjugates and compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2220939B (en) * 1988-06-10 1992-02-26 Medical Res Council Peptide fragments of hiv and their use in vaccines and diagnosis
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
BR9406652A (en) * 1993-03-05 1996-09-10 Cytel Corp Composition
EP0728764A4 (en) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide capable of inducing immune response against hiv and aids preventive or remedy containing the peptide
WO1997034621A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla-a2.1 binding peptides and their uses
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A2 (en) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of HIV-1 infection
WO1992022577A1 (en) * 1991-06-17 1992-12-23 Neovacs Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US5736142A (en) * 1993-09-14 1998-04-07 Cytel Corporation Alteration of immune response using pan DR-binding peptides
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
WO1999049893A1 (en) * 1998-03-31 1999-10-07 Trustees Of Boston University Methods for designing molecular conjugates and compositions thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GSP 11 August 1998 (1998-08-11), retrieved from EBI Database accession no. AAW43064 *
DATABASE GSP 12 May 1993 (1993-05-12), retrieved from EBI Database accession no. AAR30963 *
DATABASE GSP 21 February 1990 (1990-02-21), retrieved from EBI Database accession no. AAP90212 *
See also references of WO0124810A1 *

Also Published As

Publication number Publication date
JP2003510099A (en) 2003-03-18
AU1075001A (en) 2001-05-10
JP4873810B2 (en) 2012-02-08
CA2386499A1 (en) 2001-04-12
EP1225907A1 (en) 2002-07-31
WO2001024810A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
EP1225907A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN IMMUNODIC VIRUS-1 (HIV-1) BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS
ID30380A (en) OBSERVATION OF VIRUS INFECTION USING ANTIGEN BINDING PROTEIN
EP1244465A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSE TO PROSTATE CANCER BY MEANS OF PEPTIDE AND NUCLEIC ACID COMPOUNDS
EP1732598A4 (en) INDUCING CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMAVIRUS USING PEPTIDE COMPOSITIONS AND NUCLEIC ACIDS
FR16C1012I2 (en) THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
DE60324178D1 (en) THIAZOLIDIN-4-ONES TO HUMAN HYAK3 PROTEINS
ATE413188T1 (en) HUMAN PAPILLOMAVIRUS VACCINE FORMULATIONS
DE60138146D1 (en) Early diagnosis of conformational diseases
EA200000274A3 (en) METHODS OF OBTAINING AND INTERMEDIATE CONNECTIONS FOR OBTAINING ANTI-TRAY COMPOUNDS
DK1210113T3 (en) Combined vaccine preparations
EA200300381A1 (en) NUCLEIC ACIDS AND POLYPEPTIDES OF THE NEW RECEPTOR
IS7133A (en) Derivation of beta-amyloid - T-cell antibody vaccine
ATE447947T1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF INSULINRESIENCE
EP1246644A4 (en) INDUCTION OF CELLULAR IMMUNE RESPONSES TO HUMAN PAPILLOMA VIRUS USING PEPTIDES AND NUCLEIC ACID COMPOSITIONS
EP1547588A4 (en) PREPARATION OF MOLLE CAPSULE
DE50014699D1 (en) Medical instrument for the preparation of tissue
DE60223841D1 (en) MEDICAL USE OF GSK3-INHIBITABLE OXINDOL DERIVATIVES
PT1119557E (en) DERIVATIVES OF INDENE- NAFTO- AND BENZOCYCLOHEPTA-DI-HYDROTIAZOLE ITS PREPARATION AND ITS USE AS ANORECTICAL MEDICINES
ATE279193T1 (en) PHARMACEUTICAL PREPARATION OF MOXIFLOXACIN
NO20041802L (en) Antibodies to human tissue factor
EP1063592A4 (en) PROCESSOR OF DOCUMENTS
EP1460900A4 (en) SEPARATE HUMAN PROTEINS
EP1185545A4 (en) CD4-INDEPENDENT HIV ENVELOPE PROTEINS AS VACCINE AND THERAPEUTICA
EP1425039A4 (en) IMMUNOREACTIVE PEPTIDES OF HUMAN PAPILLOMAVIRUS
EP1416957A4 (en) TREATMENT OF IMMUNE DISEASES AND B-CELL DISEASES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CELIS, ESTEBAN

Inventor name: KUBO, RALPH, T.

Inventor name: SETTE, ALESSANDRO

Inventor name: LIVINGSTON, BRIAN, D.

Inventor name: SOUTHWOOD, SCOTT

Inventor name: CHESNUT, ROBERT

Inventor name: SIDNEY, JOHN

Inventor name: BAKER, DENISE, MARIE

A4 Supplementary search report drawn up and despatched

Effective date: 20050506

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071201